(Q44427254)

English

Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia

scientific article published on April 15, 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 December 2017

Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia (English)

1 reference

Europe PubMed Central

2 December 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

circulatory system

1 reference

based on heuristic

inferred from title

cardiovascular disease

1 reference

based on heuristic

inferred from title

2

object named as

Paul M Ridker

1 reference

Europe PubMed Central

2 December 2017

author name string

Gavin J. Blake

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12727581

29 December 2023

Paul M. Ridker

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12727581

29 December 2023

Karen M. Kuntz

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12727581

29 December 2023

language of work or name

0 references

publication date

1 April 2003

1 reference

Europe PubMed Central

2 December 2017

15 April 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12727581

29 December 2023

full work available at URL

https://api.elsevier.com/content/article/PII:S0002934303000743?httpAccept=text/xml

1 reference

10.1016/S0002-9343(03)00074-3

https://api.crossref.org/works/10.1016/S0002-9343(03)00074-3

29 December 2023

https://api.elsevier.com/content/article/PII:S0002934303000743?httpAccept=text/plain

1 reference

10.1016/S0002-9343(03)00074-3

https://api.crossref.org/works/10.1016/S0002-9343(03)00074-3

29 December 2023

American Journal of Medicine

1 reference

Europe PubMed Central

2 December 2017

114

1 reference

Europe PubMed Central

2 December 2017

6

1 reference

Europe PubMed Central

2 December 2017

485-494

1 reference

Europe PubMed Central

2 December 2017

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900074-3

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900074-3

7 January 2021

Using cost-effectiveness analysis to target cholesterol reduction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900074-3

7 January 2021

Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900074-3

7 January 2021

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900074-3

7 January 2021

Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900074-3

7 January 2021

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900074-3

7 January 2021

C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900074-3

7 January 2021

Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900074-3

7 January 2021

C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900074-3

7 January 2021

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900074-3

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900074-3

7 January 2021

Should statin therapy be considered for patients with elevated C-reactive protein? The need for a definitive clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900074-3

7 January 2021

Markov models in medical decision making: a practical guide.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900074-3

7 January 2021

Cardiovascular disease risk profiles.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900074-3

7 January 2021

Age-related trends in short- and long-term survival after acute myocardial infarction: a 20-year population-based perspective (1975-1995).

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900074-3

7 January 2021

Cost-effectiveness of ticlopidine in preventing stroke in high-risk patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900074-3

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900074-3

7 January 2021

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900074-3

7 January 2021

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900074-3

7 January 2021

Cholesterol reduction and the risk for stroke in men. A meta-analysis of randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900074-3

7 January 2021

Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900074-3

7 January 2021

The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900074-3

7 January 2021

Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900074-3

7 January 2021

Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900074-3

7 January 2021

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900074-3

7 January 2021

Cost-effectiveness of captopril therapy after myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900074-3

7 January 2021

Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). AFCAPS/TexCAPS Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900074-3

7 January 2021

The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900074-3

7 January 2021

Cost-effectiveness of statins

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900074-3

7 January 2021

Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900074-3

7 January 2021

The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900074-3

7 January 2021

Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900074-3

7 January 2021

Cost-effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900074-3

7 January 2021

Cost-effectiveness of screening for colorectal cancer in the general population.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900074-3

7 January 2021

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900074-3

7 January 2021

Identifiers

10.1016/S0002-9343(03)00074-3

1 reference

Europe PubMed Central

2 December 2017

1 reference

Europe PubMed Central

2 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44427254&oldid=2040135228"